ReviewJournal of Korean Neurosurgical Society2015
Recent Advancements of Treatment for Leptomeningeal Carcinomatosis.
Review in Journal of Korean Neurosurgical Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Intrathecal chemotherapy for leptomeningeal disease in high-grade gliomas: a systematic review.Journal of neuro-oncology · 2024Pooled it
- Leptomeningeal Metastasis from Gastric Signet Ring Cell Carcinoma: A Case Report and Literature Review.Journal of gastrointestinal cancer · 2026Review
- Re-evaluation of cerebrospinal fluid cytology for diagnosis of leptomeningeal metastasis based on radiological features, patient symptoms/signs, and clinical follow-up.Journal of neuro-oncology · 2026Article
- Fate of Brain Metastasis With Cerebrospinal Fluid Space Invasion Based on MRI Findings: Clinical Features and Factors Affecting Progression to Overt Leptomeningeal Metastasis.Brain tumor research and treatment · 2026Article
- Leptomeningeal carcinomatosis in gastric cancer: a single-center retrospective analysis of 86 cases.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Article
- Exploratory profiling of metabolites in cerebrospinal fluid using a commercially available targeted LC-MS based metabolomics kit to discriminate leptomeningeal metastasis.Cancer & metabolism · 2025Article
- Integration of continuous lumbar drainage and third-generation EGFR-TKI in managing leptomeningeal metastasis-induced life-threatening intracranial hypertension: a case report.Frontiers in oncology · 2025Article
- Differential Diagnosis of a Well-Enhancing Intracisternal Lesion in a Breast Cancer Patient.Brain tumor research and treatment · 2025Article
- Complete Remission of Dural-Based Leptomeningeal Metastasis in Patient With Non-Small Cell Lung Cancer by Osimertinib.Brain tumor research and treatment · 2024Article
- Extracellular Vesicles from Cerebrospinal Fluid of Leptomeningeal Metastasis Patients Deliver MiR-21 and Induce Methotrexate Resistance in Lung Cancer Cells.International journal of molecular sciences · 2024Article
- Systemic absorption of intrathecal methotrexate.BMJ case reports · 2023Article
- Cerebrospinal fluid neurofilament light chain as a potential prognostic biomarker for leptomeningeal metastasis.Oncology letters · 2022Article
- Lumboperitoneal Shunt Combined With Ommaya Reservoir Enables Continued Intraventricular Chemotherapy for Leptomeningeal Metastasis With Increased Intracranial Pressure.Brain tumor research and treatment · 2022Article
- Exploratory Profiling of Extracellular MicroRNAs in Cerebrospinal Fluid Comparing Leptomeningeal Metastasis with Other Central Nervous System Tumor Statuses.Journal of clinical medicine · 2021Article
- CYFRA 21-1 levels in cerebrospinal fluid as a putative therapeutic monitoring biomarker for patients with leptomeningeal carcinomatosis: A pilot study.Cancer biomarkers : section A of Disease markers · 2020Article
- Fate of nanoparticles in the central nervous system after intrathecal injection in healthy mice.Scientific reports · 2019Article
- Association of MRI findings with clinical characteristics and prognosis in patients with leptomeningeal carcinomatosis from non-small cell lung cancer.Journal of neuro-oncology · 2019Article
- Choroid Plexus Carcinoma in Adults: Two Case Reports.Brain tumor research and treatment · 2019Article
- Clinical outcome of cerebrospinal fluid shunts in patients with leptomeningeal carcinomatosis.World journal of surgical oncology · 2019Article
- Diagnostic and prognostic values of cerebrospinal fluid CYFRA 21-1 in patients with leptomeningeal carcinomatosis.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of Leptomeningeal carcinomatosis (LMC) from solid cancers has not advanced noticeably since the introduction of intra-cerebrospinal fluid (CSF) chemotherapy in the 1970's. The marginal survival benefit and difficulty of intrathecal chemotherapy injection has hindered its wide spread use. Even after the introduction of intraventricular chemotherapy with Ommaya reservoir, frequent development of CSF flow disturbance, manifested as increased intracranial pressure (ICP), made injected drug to be distributed unevenly and thus, the therapy became ineffective. Systemic chemotherapy for LMC has been limited as effective CSF concentration can hardly be achieved except high dose methotrexate (MTX) intravenous administration. However, the introduction of small molecular weight target inhibitors for primary cancer treatment has changed the old concept of 'blood-brain barrier' as the ultimate barrier to systemically administered drugs. Conventional oral administration achieves an effective concentration at the nanomolar level. Furthermore, many studies report that a combined treatment of target inhibitor and intra-CSF chemotherapy significantly prolongs patient survival. Ventriculolumbar perfusion (VLP) chemotherapy has sought to increase drug delivery to the subarachnoid CSF space even in patients with disturbed CSF flow. Recently authors performed phase 1 and 2 clinical trial of VLP chemotherapy with MTX, and 3/4th of patients with increased ICP got controlled ICP and the survival was prolonged. Further trials are required with newly available drugs for CSF chemotherapy. Additionally, new LMC biologic/pharmacodynamic markers for early diagnosis and monitoring of the treatment response are to be identified with the help of advanced molecular biology techniques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.